Publication date: Jan 26, 2025
We examined the impact of the COVID-19 consortium recommendations on the surgical management of breast cancer during the first year of the pandemic. Patients with newly diagnosed ER + DCIS, ER- DCIS, AJCC Stage cT1-2N0-1 ER + , HER2-, HER2 + , and triple negative breast cancer were identified from the National Cancer Database from 2018 to 2021. An interrupted time series design evaluated differences in surgical delay and use of neoadjuvant chemotherapy/immunotherapy (NAC) and endocrine therapy (NET) before and after the pandemic. A total of 895116 female patients were included in the study with a mean age of 61. 7 years. Time to surgery decreased by an average 5. 5 days from January 2020 to May 2020 for all breast cancer types, corresponding with a 62. 2% decrease in breast cancer diagnoses per month from January 2020 to April 2020. The use of NET increased from 5. 6 to 23. 6% from January to March 2020 for patients with ER + DCIS and 8. 0 to 31. 1% for ER + cT1-2N0 cancer (both p
| Concepts | Keywords |
|---|---|
| 5days | Breast cancer |
| Breast | COVID-19 pandemic |
| Chemotherapy | Neoadjuvant therapy |
| Ct1 | Time to surgery |
| January |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | breast cancer |
| pathway | KEGG | Breast cancer |
| disease | MESH | ER+DCIS |
| disease | MESH | triple negative breast cancer |
| disease | MESH | Cancer |
| drug | DRUGBANK | Acetylcysteine |